Health · Healthcare & Policy · 3 hrs ago
US health officials send peptide compounding plan to White House
US health officials have sent a peptide policy to the White House for review.
The plan is called an interim access policy and concerns compounding pharmacies, which prepare medicines.
It could let these pharmacies temporarily produce and sell some previously restricted peptides.
Peptides are a class of substances that include injections, and some have become popular among followers of Health Secretary Robert F. Kennedy Jr. The plan has not yet been approved; it is under review by the White House Office of Management and Budget.
The review will determine whether the temporary access plan moves forward.
The available details do not say when a decision is expected.
The Food and Drug Administration submitted a peptide “interim access policy” to the White House for review, according to a government filing.
The plan would allow specialty pharmacies to produce certain peptides, according to MedPage Today.
The Hill reported that the policy would reportedly let compounding pharmacies temporarily produce and sell previously restricted peptides.
The articles describe peptides as injections that have become popular among followers of Health Secretary Robert F. Kennedy Jr.
- Who
- The Food and Drug Administration submitted the policy.
- What
- It sent a peptide “interim access policy” to the White House for review.
- When
- This week, according to The Hill.
- Where
- The White House is reviewing the policy.
- Why
- Not stated.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Agency
- Food and Drug Administration
- Policy
- Peptide “interim access policy
- Review destination
- White House